Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Geier

Showing results (221-230 of 249) with videos related to

Pageof 25
Sort By:
JHEP Reports : Innovation in Hepatology|February 4, 2026
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunityIgnazio Piseddu, Leonie S Jochheim, Katrin Boettcher, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Hepatology (Baltimore, Md.)|March 30, 2023
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation studyJenny Lee, Max Westphal, Yasaman Vali, et al.
Therapeutic Advances in Medical Oncology|February 24, 2026
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)Najib Ben Khaled, Ursula Ehmer, Ilja Kubisch, et al.
Cell Metabolism|March 12, 2013
Identification of a SIRT1 mutation in a family with type 1 diabetesAnna Biason-Lauber, Marianne Böni-Schnetzler, Basil P Hubbard, et al.
JHEP Reports : Innovation in Hepatology|April 7, 2023
Treating hepatitis D with bulevirtide - Real-world experience from 114 patientsChristopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, et al.
Gastroenterology|May 8, 2020
Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and NoncarriersCarolin V Schneider, Karim Hamesch, Annika Gross, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 4, 2024
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysisFerenc E Mózes, Jenny A Lee, Yasaman Vali, et al.
Pageof 25

Showing results (221-230 of 249) with videos related to

Sort By:
Pageof 25
JHEP Reports : Innovation in Hepatology|February 4, 2026
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunityIgnazio Piseddu, Leonie S Jochheim, Katrin Boettcher, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Hepatology (Baltimore, Md.)|March 30, 2023
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation studyJenny Lee, Max Westphal, Yasaman Vali, et al.
Therapeutic Advances in Medical Oncology|February 24, 2026
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)Najib Ben Khaled, Ursula Ehmer, Ilja Kubisch, et al.
Cell Metabolism|March 12, 2013
Identification of a SIRT1 mutation in a family with type 1 diabetesAnna Biason-Lauber, Marianne Böni-Schnetzler, Basil P Hubbard, et al.
JHEP Reports : Innovation in Hepatology|April 7, 2023
Treating hepatitis D with bulevirtide - Real-world experience from 114 patientsChristopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, et al.
Gastroenterology|May 8, 2020
Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and NoncarriersCarolin V Schneider, Karim Hamesch, Annika Gross, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 4, 2024
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysisFerenc E Mózes, Jenny A Lee, Yasaman Vali, et al.
Pageof 25